
Arrowhead’s RNA therapy silences two genes simultaneously
Arrowhead Pharmaceuticals has announced interim topline data from a Phase I/IIa clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both… Read More

